MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm13206216

Медицинская библиотека · Journal of clinical medicine · 2024

Secukinumab May Be an Effective Treatment Option for Axial Spondyloarthritis and Psoriatic Arthritis Patients with a History of Malignancy: Multicenter Real-Life Experience from Turkey.

Ocak Tuğba, Yağız Burcu, Ocak Birol, Yoğurtçu Özge, Başıbüyük Fatma, Tezcan Dilek, Ermurat Selime, İnanç Elif, Yamancan Gülşah, Albayrak Fatih, Sağır Rabia Pişkin, Bayındır Akbaş Ayşe Nur, Cüre Osman, Coşkun Belkıs Nihan, Yolbaş Servet, Karasu Uğur, Kısacık Bünyamin, Koca Süleyman Serdar, Sarı İsmail, Akar Servet, Dalkılıç Ediz, Pehlivan Yavuz

СтатьяПеревод в очереди

Аннотация

Background

Secukinumab is a monoclonal antibody against interleukin 17 approved for patients with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis. Treating axSpA and PsA patients with a history of malignancy is a challenge. While initial results on the applicability of secukinumab in this patient group are positive, the number of studies on this topic remains limited. This study aimed to investigate the drug's survival time and the efficacy and safety of secukinumab treatment in this specific patient group.

Methods

This retrospective study included 30 patients with a history of malignancy who were followed up in rheumatology outpatient clinics in 12 centers throughout Turkey and treated with secukinumab between May 2018 and March 2024 with a diagnosis of axSpA and PsA.

Results

The mean follow-up time was 29.8 ± 19.3 months. The drug retention rate was 89.7% after 12 months and 80.6% after 24 months. The most common tumor in our study was papillary thyroid carcinoma (n = 5, 16.7%). During follow-up, local tumor recurrence was observed in a patient with urothelial carcinoma of the bladder.

Conclusions

In the largest cohort reported to date, treatment with secukinumab in axSpA and PsA patients with a history of malignancy was not shown to cause oncologic recurrence except for one local tumor recurrence. Drug retention rates were also high, and disease activation and function improved compared to baseline. Therefore, secukinumab could be a safe and effective option for this patient group.

Для цитирования: Ocak Tuğba, Yağız Burcu, Ocak Birol, Yoğurtçu Özge, Başıbüyük Fatma, Tezcan Dilek, Ermurat Selime, İnanç Elif, Yamancan Gülşah, Albayrak Fatih, Sağır Rabia Pişkin, Bayındır Akbaş Ayşe Nur, Cüre Osman, Coşkun Belkıs Nihan, Yolbaş Servet, Karasu Uğur, Kısacık Bünyamin, Koca Süleyman Serdar, Sarı İsmail, Akar Servet, Dalkılıç Ediz, Pehlivan Yavuz. Secukinumab May Be an Effective Treatment Option for Axial Spondyloarthritis and Psoriatic Arthritis Patients with a History of Malignancy: Multicenter Real-Life Experience from Turkey.. Journal of clinical medicine. 2024. DOI: 10.3390/jcm13206216.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.